Amid equine influenza virus (EIV) season, a new Zoetis study showed FLUVAC INNOVATOR® to be cross-reactive against three emerging World Organization for Animal Health (OIE) equine influenza isolates.
The study demonstrated sera from horses vaccinated with EIV vaccine FLUVAC INNOVATOR EHV 4/1 or FLUVAC INNOVATOR 5 were cross-reactive against:
· Ayrshire 2013 (AY/13), European clade 2 isolate1
· Kentucky 2014 (KY/14), North American clade 1 isolate1
· Texas 2012 (TX/12), North American clade 1 isolate1
The vaccinates demonstrated at least 97.4% cross-reactivity to these three recent EIV isolates. These high rates of seroconversion demonstrated that FLUVAC INNOVATOR continues to be immunologically relevant against newly emerging North American clade 1 and European clade 2 EIV strains.
“These are the most recent OIE isolates that we have on file at the OIE reference lab at the University of Kentucky,” said Robert Holland, DVM, PhD, director of Zoetis Outcomes Research. “In result, there were good cross-reactive antibodies when vaccinated with Kentucky/97 FLUVAC INNOVATOR against those strains.”